Company profile: NovaDigm Therapeutics
1.1 - Company Overview
Company description
- Provider of vaccines that protect patients from contracting fungal and bacterial infections.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NovaDigm Therapeutics
Revagenix
HQ: United States
Website
- Description: Provider of infectious disease therapeutics, including a late-preclinical broad-spectrum antimicrobial for cUTI, HABP, VABP, neonatal sepsis and BSI; a novel agent to reduce care burden in chronic pulmonary infections; a treatment with a novel mechanism for challenging Gram-negative infections; and an on-hold pipeline of Gram-negative antibacterials that can be activated within 12-18 months.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Revagenix company profile →
Micronics
HQ: United States
Website
- Description: Provider of near-patient in vitro diagnostic products for disease diagnosis, prognosis, and treatment monitoring in the United States and internationally, including the PanNAT molecular diagnostic system, a point-of-care testing instrument.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micronics company profile →
NanoView Biosciences
HQ: United States
Website
- Description: Provider of proprietary products supporting research, translation and delivery of precision medicine, built on a novel platform that uniquely identifies and characterizes exosomes. Offers high-throughput, cost-effective analysis, including Leprechaun for lentivirus and exosome biophysical characterization, contaminant detection, and concentration measurement using fluorescence and antibody-based methods.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoView Biosciences company profile →
Durata Therapeutics
HQ: United States
Website
- Description: Provider of late-stage clinical development of novel antibiotics for infectious diseases, focused on Vicuron’s antibiotic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Durata Therapeutics company profile →
Inhibikase Therapeutics
HQ: United States
Website
- Description: Provider of cellular Abelson tyrosine kinase inhibitor therapeutics and platforms for infections and other diseases. Includes Risvodetinib (IkT-148009), an oral drug aimed at halting and reversing Parkinson’s progression in brain and GI; IkT-001Pro, a prodrug of imatinib mesylate for blood and stomach cancers with fewer on-dosing side effects; IkT-01427 to prevent PML; and the RAMP Drug Innovation Engine and Prodrug Delivery Technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inhibikase Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NovaDigm Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NovaDigm Therapeutics
2.2 - Growth funds investing in similar companies to NovaDigm Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NovaDigm Therapeutics
4.2 - Public trading comparable groups for NovaDigm Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →